Xencor, Inc. (NASDAQ:XNCR) Receives Average Recommendation of "Moderate Buy" from Brokerages

Key Points

• Analyst consensus is “Moderate Buy” among 10 covering firms, with five buy ratings, one strong buy, three holds and one sell. The average 12-month price target is $31.12, above the reported $23.80 share price.
• Recent analyst actions were mixed: Cantor Fitzgerald raised its target to $44 and maintained an overweight rating, while Wedbush lifted its target to $30; Bank of America maintained a neutral rating at $26 and Truist cut its target to $27 while retaining a buy rating.
• Xencor exceeded quarterly expectations, reporting an adjusted loss of $0.29 per share versus the $0.80 expected loss and revenue of $51.22 million versus an $18.89 million estimate. Revenue increased 17.4% year over year, though the company remained unprofitable.

Xencor, Inc. (NASDAQ:XNCR - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the ten analysts that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, three have given a hold rating, five have issued a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $31.12.

A number of analysts recently issued reports on the stock. Weiss Ratings restated a "sell (d-)" rating on shares of Xencor in a report on Monday. Wedbush lifted their price objective on shares of Xencor from $26.00 to $30.00 and gave the stock an "outperform" rating in a research report on Thursday, August 6th. Bank of America boosted their target price on shares of Xencor from $20.00 to $26.00 and gave the company a "neutral" rating in a research note on Monday, September 21st. Truist Financial reduced their target price on shares of Xencor from $29.00 to $27.00 and set a "buy" rating for the company in a research report on Tuesday, July 7th. Finally, Cantor Fitzgerald raised their price target on shares of Xencor from $43.00 to $44.00 and gave the stock an "overweight" rating in a research note on Thursday, August 6th.

Institutional Trading of Xencor

A number of large investors have recently bought and sold shares of XNCR. WINTON GROUP Ltd raised its position in shares of Xencor by 1.5% in the second quarter. WINTON GROUP Ltd now owns 106,247 shares of the biopharmaceutical company's stock valued at $1,711,000 after purchasing an additional 1,534 shares during the period. Integrated Wealth Concepts LLC purchased a new stake in shares of Xencor during the 2nd quarter valued at approximately $30,000. Squarepoint Ops LLC bought a new position in Xencor in the 2nd quarter worth approximately $459,000. Allworth Financial LP boosted its holdings in Xencor by 23.2% in the 2nd quarter. Allworth Financial LP now owns 3,436 shares of the biopharmaceutical company's stock worth $55,000 after buying an additional 646 shares during the period. Finally, Seven Fleet Capital Management LP grew its stake in Xencor by 360.4% in the 2nd quarter. Seven Fleet Capital Management LP now owns 368,305 shares of the biopharmaceutical company's stock valued at $5,930,000 after buying an additional 288,305 shares in the last quarter.

Xencor Price Performance

Shares of NASDAQ:XNCR opened at $23.80 on Friday. Xencor has a 1 year low of $10.38 and a 1 year high of $30.61. The company has a market capitalization of $1.77 billion, a PE ratio of -10.97 and a beta of 0.88. The business has a fifty day moving average price of $23.78 and a two-hundred day moving average price of $16.63.

Xencor (NASDAQ:XNCR - Get Free Report) last released its earnings results on Wednesday, August 5th. The biopharmaceutical company reported ($0.29) EPS for the quarter, topping analysts' consensus estimates of ($0.80) by $0.51. The company had revenue of $51.22 million for the quarter, compared to analysts' expectations of $18.89 million. Xencor had a negative return on equity of 28.66% and a negative net margin of 155.59%.The business's revenue for the quarter was up 17.4% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.41) EPS. Sell-side analysts anticipate that Xencor will post -3.05 earnings per share for the current year.

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company that develops engineered antibodies and cytokine therapeutics for the treatment of cancer, autoimmune diseases and other serious medical conditions. The company's platform is designed to modify antibody properties, including immune-system activation, half-life and biological activity, to create differentiated therapeutic candidates.

Xencor's proprietary XmAb technology supports its internal research programs and collaborations with other biopharmaceutical companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.